In AITL, TET2, DNMT3A, IDH2, and RHOAG17V mutations are seen at around ~80% [29, 31, 32], 20–40% [29–32], 20–30% [22, 29, 31–33], and 50–70% [29–32, 34, 35] of the cases, respectively, followed by mutations in several T-cell receptor (TCR)-related genes, such as CD28 and phospholipase C gamma 1 (PLCG1) [31, 34, 36]. This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.